NanoViricides Inc. (NNVC)

[JG36]

Sanofi's technology is quite different from NNVC's. They use nanotechnology to induce antibodies against a wide variety of flu strains, while Flucide attacks the viruses directly.

But yes, this is more competition for NNVC. There are several promising approaches to curing influenza now in development, some of them further along than Flucide. I have said before that one of the greatest risks for NNVC is that by the time Flucide has been approved there may be more effective treatments out there. These may make Flucide irrelevant or, more likely, will provide competition that will force NNVC to charge much lower prices than the "$100 a share" crowd have been assuming.